Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2875MR)

This product GTTS-WQ2875MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2875MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ370MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ9390MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ484MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ10025MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ15243MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ15616MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ15968MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11858MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW